Literature DB >> 11459709

[Cancers of unknown origin: 311 cases].

A Lortholary1, S Abadie-Lacourtoisie, O Guérin, M Mege, G D Rauglaudre, E Gamelin.   

Abstract

Carcinoma of unknown primary site has been defined as a metastatic disease without known primary site (upon clinical, radiological or endoscopic examination) at the initial therapeutic decision. The incidence of such carcinomas is between 1.6 and 15% of all adult's tumors. The goals of this retrospective and monocentric study were 1) the incidence of these carcinoma; 2) the utility to identify the primary site; 3) the efficacy of treatment in terms of survival; and 4) the prognostic factors to optimize strategic choices. Between January 1980 to December 1995, 311 cases were identified; this represents 1.6% of all cases treated in our center. Histological analyses of metastases revealed adenocarcinoma: 164 cases (92 males, 72 females; 29 well differentiated, 11 poorly differentiated and 41 undifferentiated); squamous cell carcinoma: 90 cases (78 males, 12 females); undifferentiated carcinoma: 27 cases (21 males, 6 females); neuro-endocrine tumor: 10 cases; and others: 20 cases. Median age was 61.1 years (30-94). Half of the patients had a PS between 0 and 1. The carcinoma was revealed by only one site of metastases in 35% of the cases (lymph node 72.9%, bone 35.5%, liver 19.4% and lung 16.5%). The primary carcinoma was found in only 6% of the cases. Median survival of all patients was only 9 months. Multivariate analyses by the Cox method show four positive prognostic factors: sex (female), performance status (PS < 2), histological analyses (squamous cell carcinoma), only one site of metastases.

Entities:  

Mesh:

Year:  2001        PMID: 11459709

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  3 in total

1.  Cytogenetic profile of unknown primary tumors: clues for their pathogenesis and clinical management.

Authors:  Dimitra Pantou; Haroula Tsarouha; Anna Papadopoulou; Louiza Mahaira; Ioannis Kyriazoglou; Nikiforos Apostolikas; Sophia Markidou; Theoni Trangas; Nikos Pandis; Georgia Bardi
Journal:  Neoplasia       Date:  2003 Jan-Feb       Impact factor: 5.715

Review 2.  [Metastases with CUP syndrome].

Authors:  S Seeber; D Strumberg
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

3.  ECOG is as independent predictor of the response to chemotherapy, overall survival and progression-free survival in carcinoma of unknown primary site.

Authors:  Rocío Grajales-Álvarez; Ana Martin-Aguilar; Juan A Silva; Jaime G De La Garza-Salazar; Erika Ruiz-García; César López-Camarillo; Laurence A Marchat; Horacio Astudillo-De La Vega
Journal:  Mol Clin Oncol       Date:  2017-04-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.